RxSpan MD research and fine print
The current terms identify RxSpan MD LLC at a Beverly Hills address. RxSpan MD operates the platform and says independent medical professionals make prescribing decisions. It also says the platform does not manufacture compounded medication.
The homepage identifies Lion MD as the medical team and names Ana Lisa Carr, MD, NPI 1689841744, and Kelly James Tenbrink, MD, NPI 1346482684. Both CMS NPI records were active during research, with family medicine listed for Dr. Carr and emergency medicine for Dr. Tenbrink.
The homepage names Belmar Pharmacy, Strive Pharmacy, Epiq Scripts, and Casa Pharma Rx. It does not identify which pharmacy will dispense a particular prescription before evaluation, so a general pharmacy name is not treated as product-specific evidence.
The public flow begins with account and case creation followed by a medical intake. A clinician may decide from the intake or request a telehealth appointment when more information is needed. Any prescription remains subject to independent clinical judgment.
The homepage describes the assessment as taking about two minutes, while other calls to action use about five minutes. These are provider estimates rather than guaranteed completion or response times.
Category pages say checkout precedes clinician review and a prescription is not guaranteed. A public Telehealth Visit product says a patient who is not prescribed medication is charged $80. When medication is prescribed, the full consultation, medication, and shipping amount is charged.
The public product endpoint returned 133 records during research, with 85 marked visible. The linked shopping experience exposes a smaller catalog. This review follows accessible category pages and does not turn invisible or unlinked records into active services.
Seven cards cover the most defensible single-ingredient products. Marketing names, term rows, dose labels, route variants, and multi-ingredient formulas do not become separate therapies.
Compounded semaglutide injection costs $249 for one month, $657 for three, $1,194 for six, or $2,327 for twelve. Monthly equivalents are $249, $219, $199, and $193.92. Their unweighted mean is $215.23, displayed as Avg. $215/mo.
Compounded tirzepatide injection costs $329 for one month, $927 for three, $1,734 for six, or $3,228 for twelve. Monthly equivalents are $329, $309, $289, and $269. Their unweighted mean is $299.
NAD+ injection costs $249 for one month, $597 for three, $997 for six, or $1,797 for twelve. The monthly equivalents average $190.98, displayed as Avg. $191/mo. Exact strength, quantity, source ingredient, schedule, and pharmacy are not public.
Sermorelin injection costs $199 for one month, $549 for three, $997 for six, or $1,797 for twelve. The monthly equivalents average $174.48, displayed as Avg. $174/mo. Exact strength, quantity, schedule, monitoring, and pharmacy are not public.
The selected single-month prices are $69 for a minoxidil tablet plan, $59 for a dutasteride capsule plan, and $89 for tadalafil. Exact strength, quantity, regimen, and pharmacy are not visible, so none is enabled for comparison.
The site currently advertises 10% off any order with code STARTNOW. For example, a $2,327 annual semaglutide term becomes $2,094 and is displayed as about $175 per month. Temporary discounts are excluded from standard averages.
Category selectors label longer plans prepaid and describe monthly, quarterly, semiannual, and annual choices. The same interface says plans auto-renew and may be changed or canceled at any time.
The terms do not state the cancellation method, required notice, renewal date, current-cycle refund eligibility, general refund policy, or early-termination calculation. A patient considering a long term should capture the final total and those rules before payment.
Category pages say prices include the consultation, medication when prescribed, supplies, shipping, and follow-up support. No universal laboratory panel, testing cadence, or laboratory price is disclosed.
No general insurance, prior-authorization, superbill, HSA, or FSA policy was located. CareCredit financing is advertised and remains subject to credit approval.
The weight-loss category lists Ozempic at $1,299 for the first month, Wegovy at $1,349, and Zepbound at $1,069. A separate current organization-data response lists Zepbound at $500. This conflict keeps brand-name products editorial-only and makes checkout authoritative.
The site lists semaglutide and tirzepatide capsules, but public pages do not establish enough formulation, active-ingredient form, strength, quantity, administration conditions, or pharmacy detail to compare them with injections or approved oral medication.
NAD+ nasal spray and flex-dose tablets and a sermorelin orally dissolving tablet are distinct dosage forms. They remain outside the injection cards because route and formulation differences affect use and comparison.
The sexual-health section includes sildenafil with Pycnogenol, tadalafil, tadalafil with caffeine and L-citrulline, vardenafil, and Trimix T105. Only single-ingredient tadalafil receives a card. Other products need exact amounts, strength, quantity, and route detail.
The hair section includes products involving minoxidil, finasteride, dutasteride, tretinoin, biotin, melatonin, and other ingredients. Only clearly labeled single-ingredient minoxidil tablet and dutasteride capsule products receive cards.
Current linked categories do not expose a consumer testosterone or women's-HRT purchase section. Hormone records in the product feed are not represented as active orderable programs.
The homepage advertises free expedited delivery. A public catalog item says Overnight Cold Shipping. The site does not publish one universal delivery estimate, cold-chain standard, temperature-excursion process, damage window, or replacement rule.
The platform says it supports all 50 states but qualifies service by clinician licensure and law. No medication-specific state matrix is public, so platform access does not guarantee every treatment in every state.
The current footer lists info@rxspanmd.com. The site advertises appointments and messaging but does not publish staffed hours, a response target, an emergency channel, or separate billing, clinical, and shipping escalation paths.
The privacy policy describes collection of identity, account, payment, device, usage, and health information. It describes sharing with clinicians, pharmacies, service providers, legal authorities when required, and parties involved in a business transfer.
The site displays a LegitScript seal and checker link. The checker result was not independently retrieved during this review, so the seal is recorded as provider-presented rather than as independent certification evidence.
Compounded drugs are not FDA approved and do not undergo FDA premarket review for safety, effectiveness, or quality. FDA's current GLP-1 guidance raises concerns about dosing errors, salt forms, shipping temperature, and multi-dose vial use and says compounded GLP-1 products should be used only when a patient's needs cannot be met by an approved drug.
FDA has warned sterile compounders to use drug-suitable NAD+ ingredients and described adverse events consistent with excess endotoxin exposure. This is general safety context, not evidence that an RxSpan MD pharmacy violated the requirement.
RxSpan MD's Katalys program is approved and its issued tracking URL was redirect-verified. The public discount is documented but not placed under the AllyRx CTA because affiliate compatibility is unconfirmed. Payout and EPC did not affect the score or conclusions.
- Seven normalized cards replace dozens of term, dose, route, and branded labels.
- Multi-term prices use monthly equivalents with temporary promotions excluded.
- The site names Lion MD, two clinicians, and four pharmacies, but assignments remain patient-specific.
- Checkout precedes the prescription decision, and a public listing describes an $80 fee when no medication is prescribed.
- Prepaid plans auto-renew without a complete public cancellation and refund standard.
- Zepbound pricing conflicts across two current first-party data surfaces.
- Platform support in 50 states does not establish medication-specific nationwide eligibility.
- Compounded GLP-1 and NAD+ claims use current FDA context without unsupported pharmacy accusations.